United Therapeutics Corporation - Common Stock (NQ:UTHR)

United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting

October 13, 2025

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

2 Growth Stocks with All-Star Potential and 1 Facing Headwinds

October 08, 2025

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results ↗

September 02, 2025

Via Stocktwits

This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside ↗

September 02, 2025

Via Stocktwits

This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

September 26, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

Via Benzinga

United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis

September 19, 2025

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

1 Momentum Stock to Target This Week and 2 We Brush Off

September 19, 2025

United Therapeutics currently trades at $412.41 and has been a dream stock for shareholders. It’s returned 308% since September 2020, tripling the S&P 500’s 103% gain. The company has also beaten the...

3 Big Reasons to Love United Therapeutics (UTHR)

September 19, 2025

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together ↗

Topics Stocks

August 27, 2025

Via Stocktwits

United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Top Peter Lynch-Style GARP Investment ↗

September 17, 2025

United Therapeutics (UTHR) aligns with Peter Lynch's GARP strategy, featuring strong EPS growth, a PEG below 1, zero debt, and robust financial health.

Via Chartmill

United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum

September 16, 2025

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress

September 12, 2025

United Therapeutics Price Strength Rating Jumps After Its Stock Soared 33% Last Week On Positive Drug Test Results ↗

September 10, 2025

United Therapeutics also boasts a terrific 96 Composite Rating. The Composite score combines five separate proprietary ratings into one.

Via Investor's Business Daily

Topics ETFs

Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗

September 07, 2025

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

Via Benzinga

United Therapeutics Corp (NASDAQ:UTHR): A Prime Value Investing Candidate with Strong Fundamentals ↗

September 06, 2025

United Therapeutics (UTHR) is a strong value investing candidate with low P/E, zero debt, high profitability, and excellent financial health, offering a solid margin of safety.

Via Chartmill

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results ↗

September 02, 2025

Via Benzinga

Topics Stocks

Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session. ↗

September 02, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Why Is United Therapeutics Stock Rallying On Tuesday? ↗

September 02, 2025

United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use.

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It ↗

September 02, 2025

The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition.

Via Investor's Business Daily

Tuesday's pre-market session: top gainers and losers ↗

September 02, 2025

As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 02, 2025

Via Benzinga

United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

September 02, 2025

United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 29, 2025